While GLP-1 receptor agonists and SGLT-2 inhibitors are both recommended as second-line therapies by the EASD (guidance that is followed in Portugal), offering the choice of an oral GLP-1 analog at this stage in the algorithm affords both patients and physicians more choice when developing an individualized diabetes treatment program [7, 8]. This evidence concerns the gene SLC5A2 and diabetes mellitus.